Arms	60 mg/kg/wk vs 120 mg/kg/wk of intravenous alpha1-PI, vs placebo
Duration	3 years
Primary Endpoint	Lung loss via whole lung CT densitometry (15th percentile point) in each active arm vs placebo
Other Endpoints	- Severe COPD exacerbations
	- Basal lung CT densitometry
	- Forced expiratory volume in 1 sec
	- Quality of life
Sample Size	Total of 339 subjects (80% power at 0.025 level with an assumed 20% dropout)